$VNDA News
Last published 1d ago
- 1d agoVNDANEREUS™ - The Goat of Biscayne Bay Arrives for Miami Art WeekPR NewswireVanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that "NEREUS™ – The Goat of Biscayne Bay" is arriving during Miami Art Week, offering...
- 2w agoVNDAQ3 2026 Vanda Pharmaceuticals Inc. Earnings Conference Call - VANDA PHARMACEUTICALS INCEarnings Call TranscriptsLadies and gentlemen, welcome to the Q3 2026 Vanda Pharmaceuticals, Inc. earnings call. All lines have been placed on mute to prevent any background noise, and after the speaker's remarks, we will conduct a question and
- 2w agoVNDAVanda Pharmaceuticals Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoVNDAVanda Pharmaceuticals Reports Third Quarter 2026 Financial ResultsPR NewswireQ3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026Announced positive results from
- 2w agoVNDAVanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced VomitingPR NewswireNEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomitingKey ResultsAny vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative
- 3w agoVNDAVanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026PR NewswireConference Call and Webcast to FollowWASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2026 on Wednesday, October
- 4w agoVNDAVanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramPR NewswirePhase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpointConsistent with prior studies, VQW-765 was safe and well toleratedWASHINGTON, Oct. 14, 2026 /PRNewswire/ --
- 1mo agoVNDAVanda Pharmaceuticals Announces Presentation at 2026 EADV Annual MeetingPR NewswireVanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, ...
- 1mo agoVNDAVanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase DisorderPR NewswireVanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg...
- 2mo agoVNDAVanda Pharmaceuticals Announces Participation at September 2026 Investor ConferencesPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in ...
- 2mo agoVNDAVanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European CommissionPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the...
- 2mo agoVNDANEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.PR NewswireVanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick...
- 3mo agoVNDAQ2 2026 Vanda Pharmaceuticals Inc. Earnings Conference Call - VANDA PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon and welcome to the second quarter 2026 Vanda Pharmaceuticals Incorporated Earnings Conference Call. I am Franz, and I'll be the operator assisting you today. All lines have been placed on mute to prevent a
- 3mo agoVNDAVanda Pharmaceuticals Reports Second Quarter 2026 Financial ResultsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026. "We...
- 3mo agoVNDAVanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026PR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on Wednesday, August 5, 2026,...
- 3mo agoVNDAApproval of Hetlioz, Nda #205677 (Manufacturing (CMC))FDA Approved DrugsApproval Date: 07/27/2026; Drug Name: Hetlioz, Nda #205677; Active Ingredients: TASIMELTEON; Company: Vanda Pharms Inc; Submission Status: Approval; Submission Classification: Manufacturing (CMC); Application Number: 205677
- 3mo agoVNDAVanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in EuropePR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency...
- 4mo agoVNDANEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness TreatmentPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for...
- 4mo agoVNDAVanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision SummitPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities...
- 4mo agoVNDAVanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2SPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease ...
- 5mo agoVNDAVanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular PsoriasisPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
- 6mo agoVNDAVanda Pharmaceuticals Announces Participation at May 2026 Investor ConferencesPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in ...
- 6mo agoVNDAVanda Pharmaceuticals Reports First Quarter 2026 Financial ResultsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2026....
- 6mo agoVNDAVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States...
- 6mo agoVNDAVanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States...
- 6mo agoVNDAVanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026PR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2026 on Wednesday, May 6, 2026, after ...
- 6mo agoVNDAANABVanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidencePR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of...
- 6mo agoVNDAVanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of DirectorsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April...
- 7mo agoVNDAVanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review TimelinesPR NewswireVanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget...
- 7mo agoVNDAVanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor AgonistsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the ...
- 7mo agoVNDAVanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant MethodsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal...
- 8mo agoVNDAVanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 YearsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request...
- 8mo agoVNDAVanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences ConferencePR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in...
- 8mo agoVNDAANABVanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular PsoriasisPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its...
- 8mo agoVNDAVanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric InnovationPR NewswireVanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone)...
- 8mo agoVNDAApproval of Bysanti, Nda #220358 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 02/20/2026; Drug Name: Bysanti, Nda #220358; Active Ingredients: MILSAPERIDONE; Company: Vanda Pharms Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 220358
- 9mo agoVNDAVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended...
- 9mo agoVNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026PR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday,...
- 10mo agoVNDAVanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag DisorderPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's ...
- 10mo agoVNDAVanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion SicknessPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™...
- 11mo agoVNDAVanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular PsoriasisPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
- 11mo agoVNDAVanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare ConferencePR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San...
- 11mo agoVNDAFDA Lifts Partial Clinical Hold on Tradipitant for Motion SicknessPR NewswireVanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on...
- 11mo agoVNDAVanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion SicknessPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness: Partial Clinical...
- 12mo agoVNDAVanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and VomitingPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leading biopharmaceutical company focused on the development and commercialization of innovative ...
- 1y agoVNDAVanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare ConferencePR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 Healthcare Conference in New...
- 1y agoVNDAVanda Pharmaceuticals Reports Third Quarter 2025 Financial ResultsPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2025....
- 1y agoVNDAVanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025PR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2025 on Wednesday, October 29, 2025,...
- 1y agoVNDAMonumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown ArenaPR NewswireMonumental Sports & Entertainment (MSE) today announced Vanda Pharmaceuticals (Nasdaq: VNDA), a leading global biopharmaceutical company...
- 1y agoVNDAVanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug AdministrationPR NewswireVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has agreed on a collaborative framework with the U.S. Food and Drug...